You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

World Hemophilia Day 2021, Kedrion alongside patients

Today, more than ever, the company is close to those who are in a vulnerable condition

read more 

PLASMA & BIOTHERAPIES

Rh&Life, first subject included in the study

Two hundred pregnant women to be enrolled over five countries

read more 

PLASMA & BIOTHERAPIES

KIDCARES10, first patient enrolled in pediatric PI study

Thirty patients aged 2 to 17 years old to be enrolled over five European countries

read more 
  1. EVENTS - 15-11-2019

    Kedrion keeps Hemophilia therapy debate flowing in Latin America

    A recent CLAHT Congress symposium restates current and future role of replacement therapy

    read more 
  2. CORPORATE - 16-10-2019

    FSI SGR enters Kedrion share capital

    The company continues with its growth and development strategy

    read more 
  3. EVENTS - 30-09-2019

    Kedrion reaffirms its commitment for the global eradication of Rh disease

    A worldwide initiative for maternal and fetal health launches in Florence, Italy

    read more 

Pages

For more information please contact: [email protected]